Baupost Group Increases Idenix Pharmaceuticals Stake

Seth Klarman's hedge fund firm Baupost Group has increased its stake in Idenix Pharmaceuticals (IDIX) per an amended 13D and Form 4 filed with the SEC.

Per the filings, Baupost has disclosed a 35.38% ownership stake in IDIX with over 53.3 million shares.  This means they've added to their position size by more than 16.4 million shares since November when they also added to their Idenix stake.

The Form 4 details that Baupost acquired those shares at a price of $6.5 on January 31st.  This was part of a registered direct offering from the company that Baupost took part in.  They are the company's largest shareholder.

Per Google Finance, Idenix Pharmaceuticals is "a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France."

You can view other recent portfolio activity from Baupost here.

Baupost Group Increases Idenix Pharmaceuticals Stake

Seth Klarman's hedge fund firm Baupost Group has filed a 13D with the SEC regarding shares of Idenix Pharmaceuticals (IDIX).  Per the filing, Baupost has revealed a 27.55% ownership stake with 36,910,868 shares.

This marks an increase of 38% in their position size since the end of the second quarter.   The 13D contains the standard boilerplate that they might engage in discussions with management.

Recent trading activity from Baupost is also outlined in the filing.  Klarman's firm bought the majority of their new shares on November 1st at $3.98, and in early October at prices ranging from $3.56 to $4.85.

This is the second time that Baupost has increased its stake in Idenix this year, as we also highlighted their purchase back in late January.  The main difference now is that Baupost has switched from a passive 13G filing, to a potentially activist 13D filing.

Per Google Finance, Idenix Pharmaceuticals is "a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France."

Seth Klarman's Baupost Group Increases Idenix Pharmaceuticals Position

Seth Klarman's firm Baupost Group recently filed an amended 13G with the SEC regarding its position in Idenix Pharmaceuticals (IDIX).  Per the filing, Baupost Group now owns 18.48% of the company with 24,740,200 shares.

This marks around a 106% increase in the number of shares they own since the end of the third quarter.  The filing was made due to portfolio activity on January 31st.

Per Google Finance, Idenix Pharmaceuticals "is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and Europe. The Company’s research and development focus is on the treatment of hepatitis C virus (HCV)."

You can see more of Baupost Group's portfolio activity here.